Hamilton Wealth LLC Buys 80,751 Shares of Gilead Sciences, Inc. $GILD

Hamilton Wealth LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 210.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 119,118 shares of the biopharmaceutical company’s stock after purchasing an additional 80,751 shares during the quarter. Gilead Sciences accounts for 1.2% of Hamilton Wealth LLC’s portfolio, making the stock its 22nd biggest holding. Hamilton Wealth LLC’s holdings in Gilead Sciences were worth $16,601,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Paulson Wealth Management Inc. boosted its holdings in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 67 shares in the last quarter. Essex Financial Services Inc. grew its stake in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. increased its holdings in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares in the last quarter. Alpha Cubed Investments LLC increased its holdings in shares of Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares in the last quarter. Finally, Personal CFO Solutions LLC raised its position in shares of Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 76 shares during the period. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: UBS analyst Michael Yee reiterated a Buy rating and maintained a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as sources of durable growth. Michael Yee Reiterates Buy on Gilead
• Positive Sentiment: The earnings preview highlights continued strength in Gilead’s HIV franchise, rising expectations for Yeztugo, and progress in oncology. These businesses could help support revenue growth and investor sentiment if management provides constructive guidance. Gilead to Report Q2 Earnings
• Neutral Sentiment: Gilead’s CAR-T therapies remain established products, but off-the-shelf developers are targeting market segments that approved therapies do not fully address. This could expand the broader CAR-T market while also increasing competitive pressure over time. BMS and Gilead Rule in the CAR-T Space
• Negative Sentiment: Barclays lowered its Gilead price target from $155 to $145 and assigned an Equal Weight rating, signaling more limited near-term upside despite the target remaining above the current trading level. Barclays Gilead Price Target Update
• Negative Sentiment: Analyst previews warn that Gilead may report a decline in second-quarter earnings and does not appear to have the usual combination of positive earnings revisions and estimate-beat indicators. Competitive pressure in Cell Therapy is an additional concern heading into the report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Atea Pharmaceuticals said its hepatitis C combination therapy matched Gilead’s drug in a pivotal Phase 3 trial. If approved, a competing oral regimen could threaten Gilead’s hepatitis C franchise, although commercialization and regulatory risks remain. Atea Hepatitis C Phase 3 Trial

Analysts Set New Price Targets

A number of brokerages recently issued reports on GILD. Cantor Fitzgerald reiterated an “overweight” rating on shares of Gilead Sciences in a report on Wednesday. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday. Royal Bank Of Canada lowered their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Finally, Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $157.93.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock worth $8,687,140 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 1.2%

Shares of GILD stock opened at $132.73 on Thursday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a market cap of $164.79 billion, a P/E ratio of 18.08 and a beta of 0.32. The company has a 50 day moving average of $129.68 and a 200-day moving average of $135.84. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.